PWS
CODX

Paragon Wealth Strategies’s Co-Diagnostics CODX Stock Holding History

Paragon Wealth Strategies’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-33
Closed -$8K – 87
2021
Q2 		$8K Buy
+33
New +$8.48K ﹤0.01% 202

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paragon Wealth Strategies's CODX Position: Q3 2021 in Review

Paragon Wealth Strategies sold out of Co-Diagnostics (CODX) in Q3 2021, closing a stake of 33 shares — an estimated $8K sold.

Paragon Wealth Strategies first reported a position in CODX in Q2 2021 and held it in 1 quarter. The position peaked at $8K in Q2 2021. 78 funds tracked by Wall St. Rank hold CODX as of Q3 2021.

  • Paragon Wealth Strategies reported no remaining Co-Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Paragon Wealth Strategies sold 33 Co-Diagnostics shares in Q3 2021, an estimated $8K.
  • Paragon Wealth Strategies first reported a position in Co-Diagnostics in Q2 2021 and held it in 1 quarter.
  • Paragon Wealth Strategies's Co-Diagnostics position peaked at $8K in Q2 2021.
  • 78 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2021.

Based on Paragon Wealth Strategies's 13F filing for Q3 2021, filed 29 Oct 2021.